• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular

The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • Next
  • expand A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship between QTcF Interval at First Dose (Loading Dose) and at Steady State after Treatment with AZD1305 Extended-release Tablets or Placebo when given to Patients with Documented AF.
    Study Id
    D3190C00019
    Disease
    atrial fibrillation
    Drug Name
    AZD1305
    Study Name
    D3190C00019
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Sep 15, 2009
    • D3190C00019.pdf (511 KB)
  • expand A Single-center, Single-blind, Randomized, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of AZD1305 Extended-release Capsules in Healthy Male Japanese and Caucasian Subjects
    Study Id
    D3190C00015
    Disease
    atrial fibrillation
    Drug Name
    AZD1305
    Study Name
    D3190C00015
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    May 14, 2010
    • D3190C00015.pdf (152 KB)
  • expand A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an intravenous infusion on left ventricular performance in patients with left ventricular dysfunction.
    Study Id
    D3190C00013
    Disease
    atrial fibrillation
    Drug Name
    AZD1305
    Study Name
    D3190C00013
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Nov 27, 2009
    • D3190C00013.pdf (146 KB)
  • expand To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension (ADHERENCE)
    Study Id
    NIS-CAR-ATA-2009/1
    Disease
    hypertension
    Drug Name
    Atacand
    Study Name
    NIS-CAR-ATA-2009/1
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jul 25, 2010
    • NIS-CAR-ATA-2009_1.pdf (502 KB)
  • expand Management of cardiovascular risk factors
    Study Id
    NIS-CCH-DUM-2008/2
    Disease
    cardiovascular diseases
    Drug Name
    non drug study (cardiovascular)
    Study Name
    NIS-CCH-DUM-2008/2
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Dec 2, 2010
    • NIS-CCH-DUM-2008/2.pdf (369 KB)
  • expand Quality of Life and Treatment Satisfaction of People with Type 2 Diabetes: A European Survey
    Study Id
    NIS-CEU-DUM-2008/2
    Disease
    diabetes mellitus
    Drug Name
    non drug study (cardiovascular)
    Study Name
    NIS-CEU-DUM-2008/2
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Nov 12, 2010
    • NIS-CEU-DUM-2008/2.pdf (1 GB)
  • expand A randomized, double-blind, multicentre, placebo-controlled study to evaluate the efficacy, dose-response and safety of tesaglitazar therapy in Japanese subjects with type 2 Diabetes
    Study Id
    D6160L00001
    Disease
    diabetes mellitus
    Drug Name
    Galida
    Study Name
    D6160L00001
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jan 18, 1971
    • D6160L00001.pdf (198 KB)
  • expand A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin IR Treatment twice daily in Patients with Type 2 Diabetes
    Study Id
    D6160C00058
    Disease
    diabetes mellitus
    Drug Name
    Galida
    Study Name
    D6160C00058
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jan 18, 1971
    • D6160C00058.pdf (555 KB)
  • expand An open-label, non-randomized study to evaluate the effect of tesaglitazar 1 mg once daily doses on ovulation suppression in healthy female volunteers on an combined oral contraceptive containing drospirenone and ethinyl estradiol
    Study Id
    D6160C00057
    Disease
    diabetes mellitus
    Drug Name
    Galida
    Study Name
    D6160C00057
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jan 18, 1971
    • D6160C00057.pdf (530 KB)
  • expand A Long-Term,Post treatment,Safety Follow-up,Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies
    Study Id
    D6160C00056
    Disease
    diabetes mellitus
    Drug Name
    Galida
    Study Name
    D6160C00056
    Recruiting Status
    Closed
    Protocol Status
    Not Available
    Report
    Jan 18, 1971
    • D6160C00056.pdf (556 KB)
  • Pages
  • Previous
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013